Skip to main content
ARIX BIOSCIENCE PLC logo

ARIX BIOSCIENCE PLC — Investor Relations & Filings

Ticker · ARIX ISIN · GB00BD045071 LEI · 213800OVT3AHQCXNIX43 IL Financial and insurance activities
Open in API
Filings indexed 547 across all filing types
Latest filing 2019-11-21 Regulatory Filings
Country GB United Kingdom
Listing IL ARIX

About ARIX BIOSCIENCE PLC

https://www.arixbioscience.com/

Arix Bioscience plc is a global venture capital company that specializes in the biotechnology and life sciences sectors. The firm's primary activity involves investing in and building innovative biotech companies, providing capital and strategic support from early stages, including seed, preclinical, and clinical development. Arix focuses on identifying and nurturing breakthrough advances in life sciences to accelerate the development of new medical technologies and therapies. According to public information, the company has entered into a process of liquidation.

Recent filings

Filing Released Lang Actions
Arix Bioscience Plc - Harpoon and AbbVie announce licensing and option deal
Regulatory Filings Classification · 1% confidence The document is a press release announcing a licensing and option deal between Harpoon Therapeutics and AbbVie Inc., which is noted by Arix Bioscience plc (a portfolio company). The content details a transaction involving drug development milestones, upfront payments, and future royalties. This type of announcement, concerning fundraising, financing activities, or significant corporate transactions/agreements that impact capital structure or future revenue streams, aligns best with the 'Capital/Financing Update' category. Although it is a press release, its core subject matter is a major financial/licensing agreement, making CAP more specific than the general 'RPA' or 'RNS' fallback. The document length is substantial (over 15,000 characters), indicating it is the primary announcement, not just a notification of publication.
2019-11-21 English
Arix Bioscience Plc - Autolus reports Q3 2019 financial results
Earnings Release Classification · 1% confidence The document is an announcement by Arix Bioscience plc regarding the Q3 2019 financial results of its portfolio company, Autolus Therapeutics Plc. The text explicitly states, "Autolus reports Q3 2019 financial results" and includes detailed financial tables (Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)) for the three and nine months ended September 30, 2019. This content structure—a press release summarizing period-specific financial performance with detailed tables—is characteristic of an Earnings Release (ER). Although it contains financial data, it is presented as a release announcing those results, not the comprehensive annual filing (10-K) or a standalone interim report (IR) in the regulatory filing sense, but rather the initial public announcement of the period's earnings. Since the focus is on the quarterly results announcement, ER is the most appropriate code. It is not a full Interim Report (IR) as it is presented as a press release summary, nor is it a Call Transcript (CT) or Investor Presentation (IP). Q3 2019
2019-11-07 English
Arix Bioscience Plc - Change of Broker
Regulatory Filings Classification · 1% confidence The document is a short press release (1735 characters) announcing a change in the company's corporate broker (appointment of Peel Hunt LLP alongside Jefferies International Limited). This type of announcement relates to corporate actions, investor relations, or administrative changes that do not fit the specific categories like 10-K, ER, or DIV. Since it is a specific corporate announcement that doesn't map directly to the defined categories (like MANG for board changes or CAP for financing), and it is not a report itself, the most appropriate classification is the general regulatory announcement fallback category, RNS (Regulatory Filings).
2019-11-07 English
Arix Bioscience Plc - Autolus to present new data at the ASH Annual Meeting
Report Publication Announcement Classification · 1% confidence The document is a press release issued by Arix Bioscience plc, noting an announcement made by its portfolio company, Autolus Therapeutics Plc. The content details Autolus's upcoming presentations (oral and poster) of clinical data for its drug candidates (AUTO1, AUTO2, AUTO3) at the American Society of Hematology (ASH) Annual Meeting. This type of announcement, focusing on scientific data presentation schedules and clinical trial updates, is characteristic of investor relations communication. It is not a full financial report (10-K or IR), a formal earnings release (ER), or a proxy statement. Since it is an announcement about scientific/clinical progress intended for investors, the most fitting category is Investor Presentation (IP), as it relates directly to the data that would be presented to investors, even though this specific document is the announcement *of* the presentation schedule, not the presentation itself. However, given the options, it is a communication heavily focused on clinical data updates intended for investors, which aligns closely with the spirit of an Investor Presentation (IP) or potentially a Regulatory Filing (RNS) if it were more general. Since it details specific data to be presented at a major medical conference, it is highly specific. If we strictly follow the definitions, it is an announcement about scientific progress, which often accompanies or precedes an Investor Presentation. Given the focus on clinical data and investor interest, IP is a strong candidate, but since it is a press release announcing *other* presentations, it could also be seen as a general Regulatory Filing (RNS). Let's re-evaluate based on the 'Menu vs Meal' rule. This is an announcement *about* data presentations, not the presentation slides themselves. It is a press release. Press releases announcing clinical trial updates or scientific conference participation often fall under RNS (Regulatory Filings) if they don't fit a more specific category like ER or DIV. Since 'IP' is defined as the 'Detailed presentation for investors', and this is the *announcement* of that data being presented elsewhere, RNS is the safer, broader classification for this type of corporate news release, unless the content was the actual presentation slides. Given the context of clinical data updates being disseminated via PR Newswire, RNS is the most appropriate fallback for specific, non-financial regulatory news.
2019-11-06 English
Arix Bioscience Plc - Artios expands DDR pipeline with new asset
Capital/Financing Update Classification · 1% confidence The document is a press release issued by Arix Bioscience plc, noting an announcement made by its portfolio company, Artios Pharma, regarding an in-licensing agreement for an ATR inhibitor program from MD Anderson and ShangPharma. This type of announcement details a significant business development, specifically related to asset acquisition and pipeline expansion in the biotech/pharma sector. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is an announcement of a corporate/financing activity (in-licensing deal) that strengthens the company's assets. While it relates to financing/capital structure indirectly, the core event is a strategic business transaction. Given the options, 'Capital/Financing Update' (CAP) is the closest fit as it involves acquiring rights to develop and commercialize a product, which is a form of strategic capital deployment/asset acquisition. However, since it is primarily a press release announcing a specific business deal (in-licensing), and not a general financing round or capital structure change, it could also be considered a general Regulatory Filing (RNS) if CAP is too narrow. Given the context of biotech deals, 'CAP' often covers licensing and M&A-like activities. Since it is a detailed announcement of a deal rather than a short notice, it is not RPA. I will classify it as CAP because the in-licensing of a drug candidate is a major capital/asset development event, though RNS is a possibility if CAP is strictly interpreted as fundraising. Given the focus on acquiring rights to develop/commercialize, CAP is the most specific fit among the strategic options.
2019-11-06 English
Arix Bioscience Plc - Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and details changes in voting rights held by 'Link Fund Solutions Ltd' in 'Arix Bioscience Plc'. This type of filing, which reports changes in significant share ownership crossing regulatory thresholds, directly corresponds to the definition of Major Shareholding Notification. The code for this is MRQ.
2019-10-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.